Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Alcon Research Matthew Caldwell |
---|---|
Information provided by: | Alcon Research |
ClinicalTrials.gov Identifier: | NCT00330798 |
Nepafenac 0.1% or placebo (Balanced Salt Solution, BSS), 1 drop three times daily in contralateral eyes until healed.
To determine the comparable subjective pain level healing times of corneal epithelium (time to epithelial closure) after photorefractive keratectomy (PRK), while using either the commercial topical preparation of nepafenac (0.1%) or placebo.
Condition | Intervention | Phase |
---|---|---|
Pain Following Photorefractive Keratectomy (PRK) |
Drug: nepafenac |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment |
Official Title: | A Comparison of Topical Nepafenac to Placebo in Corneal Epithelial Healing Times and Postoperative Pain Relief of Patients Status-Post Photorefractive Keratectomy: A Double-Masked Randomized Prospective Study |
Estimated Enrollment: | 66 |
Study Start Date: | February 2006 |
Ages Eligible for Study: | 19 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | FWH20060020H |
Study First Received: | May 25, 2006 |
Last Updated: | May 25, 2006 |
ClinicalTrials.gov Identifier: | NCT00330798 |
Health Authority: | United States: USAF Surgeon General’s Research Oversight Committee |
Signs and Symptoms Postoperative Complications Pain Pain, Postoperative |
Pathologic Processes |